← Leaderboards
Steve Oconnor
Shift Pharmaceuticals Holdings, Inc.
$1,157,869
Attributed
$1,157,869
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $360.9K · FY2019–25$500K$375K$250K$125K$0
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,157,869 · 4
By mechanism
R43$484,693 · 2
U44$360,937 · 1
R41$312,239 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$97,151,761
- Beth Baseler · Leidos Biomedical Research, Inc.$87,027,148
Research focus
Pharmaceutical PreparationsIn VivoDoseSafetyPreventAntisense OligonucleotidesExonsLead CandidateRattusGenesGenetic DiseasesGrantPhosphorodiamidate Morpholino OligomerProteinsMouse ModelDrug CandidateMrna PrecursorAnimalsDesignAnimal ModelIn VitroExperimental StudyMolecular GeneticsTranscript
Grant awards (4)
Anti-sense oligonucleotide inhibitors of retinoic acid signaling and reversion of retinal remodeling for mitigating vision loss$312,239
R41 · FY2025 · EY · contact PI
IND Enabling Non-Clinical Development of E1v1.11, a Morpholino Anti-Sense Oligonucleotide for the treatment of Spinal Muscular Atrophy.$360,937
U44 · FY2023 · NS · contact PI
Development of novel ASO-based therapeutics for CMT1A$256,580
R43 · FY2022 · NS · contact PI
Multi-dose pre-clinical studies in rat for E1-targeting antisense oligonucleotides$228,113
R43 · FY2019 · NS · contact PI